Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by Dwizellon Apr 05, 2019 10:30am

116 Views

Post# 29587214

RE:I’m sure Gilead will be paying close attention

bfw wrote: They’ll be very interested in seeing the full NASH data.

They like to dominate the HIV space and won’t want to see a little upstart from Montreal selling a MDR therapy along with a NASH reducing/resolving therapy to HIV patients.

I would not be shocked to see them launch a hostile takeover of TH in the next few months.

They have the firepower to really ramp Trogarzo and Egrifta revenues and to study tesamorelin in the general NASH population.

bfw

If I were them I'll make a bid rigth now. The price is so low they could probably get the comany for 12$ CAD a share. If they wait till the complete results they take the chance people will awake and the price be a lot higher for them.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario